Director's Share Dealings
June 20, 2012 - Shire plc
Number of Shares Exercise Number of Number of Average s price Shares Shares sold ale price exercised received 295,580 £8.83 159,289 116,430 £19.36789
The 116,430 Shares were sold on June 19, 2012, of which 66,430 Shares were sold to satisfy Mr Russell's personal tax liabilities.
Following these transactions Mr Russell's shareholding in the Company has increased by 42,859 Shares to 261,991 Shares. He also holds awards of stock appreciation rights, performance shares and restricted shares over 388,113 American Depositary Shares ("ADSs"). One ADS is equal to three Shares.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie Deputy Company Secretary
For further information please contact:
Investor Relations Eric Rojas email@example.com +1 781 482 0999 Sarah Elton-Farr firstname.lastname@example.org +44 1256 894157 Notes to editors SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release